« Return to News | Awards & Advancement

Marken appoints two independent directors to board

Tuesday, March 5, 2013 04:10 PM

Marken, based in Research Triangle Park, N.C., has appointed two independent directors to its board, as a result of Marken's recent restructuring completed Dec. 21, 2012.  They are Timothy C. Tyson and Michael O'Donnell.

Tyson is a veteran leader in the global pharmaceutical marketplace, currently chairman of the board of Aptuit, a global pharmaceutical services company.  He was CEO and president of Valeant Pharmaceuticals from 2003-2008.  Previously, he spent 14 years at GlaxoSmithKline in various roles, including president of global manufacturing and supply. He also has held key positions on the PhRMA board and the International Society of Professional Engineers (ISPE).

O'Donnell currently is chairman of Verna, a company specializing in infectious control products, and non-executive director of Helical Bar, a property development firm.  He has served as an independent director on the boards of seven companies since 2008. Previously, he was a managing director of LGV Capital, a private equity firm, for more than a decade.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.